Breaking Down Mastek Limited Financial Health: Key Insights for Investors

If you're tracking Mastek Limited's financial pulse, the headline Q4FY25 figures demand attention: revenue jumped to ₹905.4 crore - a 16.1% year-on-year rise - while operating EBITDA rose to ₹138.8 crore (+10.9% YoY); at the same time the 12‑month order backlog stood at ₹2,138.7 crore and the company reported total cash, equivalents and mutual funds of ₹497.0 crore as of December 31, 2024; underlying profitability shows long-term improvement with PBDIT climbing to ₹568.73 crore in March 2025 (from ₹156.32 crore in March 2019) and EPS at ₹121.5 in March 2025, even as capital-efficiency metrics signal caution - ROE slipped to 14.92% in Q2FY26 versus a five‑year average of 19.54% and ROCE eased to 19.45% - counterbalanced by a net cash position (net debt at negative ₹67 crore) and a robust interest-coverage ratio of 27.15x; growth levers include a 13.1% QoQ USD growth in healthcare, addition of 10 new clients in Q3FY25 taking active clients to 351, and operating cash flow improving to ₹395 crore, while risks to watch are rising liabilities (total liabilities grew from ₹1,864.64 crore in March 2020 to ₹3,707.25 crore in March 2025) and higher employee costs - all of which make a deeper dive into the metrics and valuation imperative for investors seeking clarity.

Mastek Limited (MASTEK.NS) - Revenue Analysis

• Q4FY25 revenue: ₹905.4 crore (up 16.1% YoY)
• Operating EBITDA Q4FY25: ₹138.8 crore (up 10.9% YoY)
• Healthcare vertical: 13.1% quarter-on-quarter growth (in USD terms)
• 12-month order backlog (as of 31 Dec 2024): ₹2,138.7 crore (up 3.4% YoY)
• New clients added in Q3FY25: 10; Total active clients: 351
• Cash, cash equivalents & fair value of mutual funds (31 Dec 2024): ₹497.0 crore

• Revenue growth led by sector demand (notably healthcare) and sustained client additions.
• Operating margin expansion maintained via scalable delivery and cost control, reflected in 10.9% rise in Operating EBITDA.
• Order backlog expansion (₹2,138.7 crore) provides near-term revenue visibility and supports revenue continuity.
• Strong liquid reserves (₹497.0 crore) underpin balance-sheet flexibility for investments or acquisitions.

Mastek Limited (MASTEK.NS) - Profitability Metrics

• Operating profit (PBDIT) rose from ₹156.32 crore in March 2019 to ₹568.73 crore in March 2025.
• Profit before tax increased from ₹133.39 crore in March 2019 to ₹459.16 crore in March 2025.
• Profit after tax grew from ₹101.47 crore in March 2019 to ₹375.93 crore in March 2025.

• Absolute profitability expansion is strong: PAT and PBT approximately tripled between Mar‑2019 and Mar‑2025.
• Net profit margin improved to 10.9% in FY25 from 10.2% in FY24, indicating better bottom‑line conversion of revenue.
• Operating profit margin dipped to 15.9% in FY25 from 16.5% in FY24, suggesting pressure on core operating efficiency despite higher absolute operating profit.
• ROE weakness: ROE in Q2FY26 (14.92%) is materially below the five‑year average (19.54%), pointing to lower capital efficiency in the recent quarter.

Mastek Limited (MASTEK.NS) - Debt vs. Equity Structure

Mastek Limited presents a low-leverage, net-cash balance-sheet profile as of March 2025, supported by strong interest coverage and multi-year asset/liability growth.

• Total debt: ₹555 crore (Mar 2025).
• Debt-to-equity ratio: 0.02 (Mar 2025).
• Net debt: negative ₹67 crore (net cash position).
• Interest coverage ratio: 27.15× - strong ability to service interest obligations.
• Depreciation charges: down 16.4% year-on-year.

Key takeaways for investors:

• Balance-sheet strength: Net cash of ₹67 crore and a 0.02 debt-to-equity ratio limit solvency risk and provide financial flexibility for M&A, buybacks, or cushion against cyclical shocks.
• Debt affordability: Interest coverage at 27.15× indicates operating earnings comfortably cover interest expense, reducing refinancing risk even if rates rise.
• Scale and obligations: Total assets and liabilities both nearly doubled from ₹1,864.64 crore (Mar 2020) to ₹3,707.25 crore (Mar 2025), reflecting business growth and corresponding balance-sheet expansion.
• Profitability accounting: A 16.4% decline in depreciation reduces non-cash expense, which can lift reported operating margins and cash-flow metrics; monitor CAPEX trends to understand sustainability.

For complementary context on shareholder composition and buying trends, see: Exploring Mastek Limited Investor Profile: Who's Buying and Why?

Mastek Limited (MASTEK.NS) - Liquidity and Solvency

• Operating cash flow (Mar 2025): ₹395 crore
• Net cash inflow (latest period): ₹79 crore
• Cash balance (30 Jun 2025): ₹549 crore (↓ from ₹622 crore on Mar 2025)
• Employee costs (Q2FY26): ₹494.46 crore (up from ₹489.96 crore in Q1FY26)
• Employee costs (FY24 → FY25): ₹1,670 crore → ₹1,859 crore
• ROCE (Q2FY26): 19.45% vs five‑year average: 70.77%

• Positive operating cash flow supports short‑term liquidity but the declining cash balance signals higher cash deployment or timing differences.
• Rising employee costs are a recurring cash outflow pressure; FY25 employee cost increase (~11.36% YoY) merits monitoring.
• ROCE deterioration from a five‑year average (70.77%) to 19.45% in Q2FY26 suggests weakened capital productivity and potential return pressure for investors.

Mastek Limited (MASTEK.NS) Valuation Analysis

• Earnings per share (EPS): ₹42.31 (Mar 2019) → ₹121.50 (Mar 2025).
• Net profit margin: 10.2% (FY24) → 10.9% (FY25).
• Operating profit margin: 16.5% (FY24) → 15.9% (FY25).
• Return on Equity (ROE): five‑year average 19.54% → 14.92% (Q2FY26).
• Return on Capital Employed (ROCE): five‑year average 70.77% → 19.45% (Q2FY26).
• Total assets: ₹1,864.64 crore (Mar 2020) → ₹3,707.25 crore (Mar 2025).

• EPS acceleration (nearly 2.9x since 2019) supports a higher absolute valuation multiple, but investors should weigh margin stability and capital returns.
• Net margin improvement (+0.7 ppt FY24→FY25) offsets some concerns from a slight compression in operating margin (-0.6 ppt).
• ROE and ROCE declines signal weaker capital efficiency versus the five‑year historical average despite asset base doubling; this can depress forward multiples if persistent.
• Asset growth (≈99% increase from Mar 2020 to Mar 2025) indicates scale expansion but has coincided with lower returns on that incremental capital.

Mastek Limited (MASTEK.NS) - Risk Factors

• Declining return on equity: ROE fell to 14.92% in Q2FY26 versus a five‑year average of 19.54%, signaling weakening capital efficiency and lower shareholder returns.
• Compression in operating margin: Operating profit margin declined from 16.5% in FY24 to 15.9% in FY25, reflecting margin pressure at the operating level.
• Rising employee costs: Employee costs reached ₹494.46 crore in Q2FY26, weighing on operating profitability and margin recovery.
• Leverage buildup: Total liabilities increased materially from ₹1,864.64 crore in March 2020 to ₹3,707.25 crore in March 2025, raising balance‑sheet risk.
• Profitability vs efficiency dichotomy: Net profit margin improved from 10.2% in FY24 to 10.9% in FY25, indicating bottom‑line improvement even as ROE and operating margin weaken.
• Debt service capacity: Interest coverage ratio stands strong at 27.15x, indicating the company currently has ample ability to service interest, but this mitigates rather than eliminates other risks.

• Key investor considerations: monitor ROE trajectory, margin stabilization efforts, trend in employee costs, and leverage dynamics relative to cash flows.
• Operational triggers to watch: quarterly changes in billing rates and utilization, large contract wins or expirations, and any shift in working capital metrics that could stress the increased liability base.

Mastek Limited (MASTEK.NS) - Growth Opportunities

Mastek Limited's recent operating and profitability trajectory, client additions and backlog expansion point to a meaningful growth runway across verticals - notably healthcare - supported by a strengthening order book and improving margins.

• Healthcare vertical: 13.1% quarter-on-quarter growth in USD terms (Q3 FY25), signaling strong demand in life sciences, healthcare payors and providers.
• Client momentum: Added 10 new clients in Q3 FY25; total active clients now 351, enhancing cross-sell and wallet-share opportunities.
• Order visibility: 12-month order backlog of ₹2,138.7 crore as of 31 Dec 2024, up 3.4% year-on-year, supporting revenue predictability for FY25-FY26.

• Levers for further growth:
  • Deepening share in healthcare given QoQ USD growth of 13.1% in Q3 FY25.
  • Monetising backlog (₹2,138.7 crore) through delivery scale and margin expansion.
  • Cross-sell/up-sell across 351 active clients and newly added logos.
  • Operational leverage evident from PBDIT expansion to ₹568.73 crore (Mar 2025).
• Key execution considerations:
  • Conversion of backlog timing and deal ramp risks.
  • Retention and enablement to sustain higher-margin service offerings.
  • Foreign-exchange movements given USD-reported vertical growth.

For historical context on strategy, ownership and how Mastek creates value, see: Mastek Limited: History, Ownership, Mission, How It Works & Makes Money